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Abstract
The diagnosis of pain nature is a troublesome task and a wrong attribution often leads to an
increase of costs and to avoidable pharmaceutical adverse reactions. An objective and spe-
cific approach to achieve this diagnosis is highly desirable. The aim of this work was to
investigate urine samples collected from patients suffering from pain of different nature by a
metabolomics approach based on 1H NMR spectroscopy and multivariate statistical analy-
sis. We performed a prospective study on 74 subjects: 37 suffering from pain (12 with noci-
ceptive and 25 with neuropathic pain), and 37 controls not suffering from any kind of chronic
pain. The application of discriminant analysis on the urine spectral profiles allowed us to
classify these two types of pain with high sensibility and specificity. Although the classifica-
tion relies on the global urine metabolic profile, the individual contribution in discriminating
neuropathic pain patients of metabolites such as choline and phosphocholine, taurine and
alanine, suggests potential lesions to the nervous system. To the best of our knowledge,
this is the first time that a urine metabolomics profile is used to classify these two kinds of
pain. This methodology, although based on a limited sample, may constitute the basis for a
new helpful tool in the clinical diagnosis.
Introduction
The diagnosis of chronic pain is still challenging for physicians in the everyday clinical setting.
This difficulty is due to the absence of a universal agreement about the description and classifi-
cation of the different typologies of pain [1]. The International Association for the Study of
Pain (IASP) defines pain as an individual, sensorial and subjective experience, characterized by
both mental and physical factors, combined with a variety of other symptoms [2]. It may be
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difficult to distinguish nociceptive pain, resulting from tissue damage (mostly inflammatory in
nature), and neuropathic pain, involving nervous system damage. There is no gold standard
for this issue [3], and often patients receive a diagnosis of mixed or uncertain pain. The recom-
mended approach to pain diagnosis relies on a “stepwise process” that includes an accurate
anamnesis, an in depth neurological examination, the performance of appropriate diagnostic
tests, and the application of pain questionnaires [2,4–8], but a certain diagnosis is reached in
only about 80% of cases [1,9]. If the diagnostic process leads to a wrong result, the treatment
will be unsatisfactory and treating the patient with an inappropriate therapy will increase the
direct and indirect costs of the illness and side effects will be unjustified.
The gold standard, as above defined, is unsatisfactory in differentiating pain types, especially
for neuropathic pain [1]. Many scientists are looking for clinical features, laboratory markers
or instrumental signs characteristic of this kind of chronic pain and uninfluenced by the sub-
jectivity of either the patient or the physician. So far, their efforts have failed to produce con-
vincing and unambiguous results that can be translated into clinical practice [10].
Among the emerging technologies, metabolomics may be a useful tool to identify a biologi-
cal signature that discriminates among different pain syndromes, helping in the diagnosis and
treatment of patients. Metabolomics is defined as the study of the complete set of low molecu-
lar weight metabolites (metabolome) within a biological fluid [11]. High Resolution 1H Nuclear
Magnetic Resonance (NMR) spectroscopy is very attractive since it is highly reproducible and
requires minimal sample preparation. Recent evidences, based on metabolomics with different
analytical platforms (1H NMR, Mass Spectrometry), on different biological matrices (plasma,
urine, cerebrospinal fluid, and tissues), from either humans or animal models [12–18], sug-
gested that this approach could be a promising tool to help in the diagnostic assessment of
pain. To the best of our knowledge, difference between neuropathic and nociceptive pain has
never been investigated. Therefore, the objective of our study was to assess whether urine meta-
bolomics profiles can differentiate neuropathic and nociceptive pain, as diagnosed on the basis
of the current clinical protocol. To this goal, we applied a metabolomics approach based on 1H
NMR analysis of urine collected from patients affected by these two different types of pain and
from a control group.
Materials and Methods
Patients and controls
This prospective study was conducted in December 2014 on consecutive patients referred to
the Pain Therapy Centres of University Hospital of Cagliari and of Columbus Clinic of the
Catholic University of Rome, both in Italy. Approval by the Institutional Review Board (Comi-
tato Etico Indipendente dell’Azienda Ospedaliero-Universitaria di Cagliari, November 17th,
2014) was obtained. Written informed consent was obtained from all subjects. Inclusion crite-
ria were all of the following: presence of pain lasting for more than 3 months; main pain inten-
sity in the last month 3 on a 0–10 Number Rating Scale (NRS); age 18 years; written
informed consent; first visit at the Pain Centres. The exclusion criteria were at least one of the
following: cancer related pain; psychiatric disorders; participation in clinical trials in the last 30
days. Ambulatory nurse administered the PainDETECT Questionnaire (PDQ) and two experi-
enced pain specialists independently examined all the patients in accordance with the current
gold standard [6] to discriminate the pain as predominantly nociceptive or neuropathic. In
case of different opinion between the two specialists, PDQ results were used to settle the con-
flict. Control urine samples were randomly chosen, from patients willing to contribute to the
research. Those patients presented and required clinical analysis in our hospital, and were not
suffering from any kind of chronic pain, neither neuropathic nor nociceptive. They were
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mostly surgical patients scheduled for elective endocrine and gynaecological surgery (mostly
thyroidectomy and hysterectomy). Unfortunately, the epidemiological and demographic char-
acteristics of this kind of patients, prevented us to perfectly match for gender and age our con-
trol sample with pain patients. Then, for each model, the best-balanced age matching available
between cases and controls has been performed, considering for age the slightest difference
available.
Sample collection and preparation for 1H NMR spectroscopy
At the moment of urine collection patients were fasting for at least 6 hours. Centrifugation of
samples at 13.000 rpm for 10 minutes at 4°C was followed by supernatants collection and
10 μL of a 10% w/w aqueous solution of sodium azide (NaN3) were added to 1 mL of superna-
tant. Samples were immediately frozen at -80°C until NMR analysis. For 1H NMR analysis, 1
mL of thawed urine was centrifuged again. An aliquot of 630 μl was mixed to 70ul of a 1.5 M
phosphate buffer solution (pH = 7.4) in D2O (99.9%, Cambridge Isotope Laboratories Inc,
Andover, USA) containing the internal standard sodium 3-(trimethylsilyl)propionate-2,2,3,3,-
d4 (TSP, 98 atom % D, Sigma-Aldrich, Milan) at a 0.6 mM final concentration, and 650 μl of
the obtained solution were transferred into a 5 mmNMR tube.
1H NMR data acquisition and processing
1H NMR experiments were carried out on a Varian UNITY INOVA 500 spectrometer (Agilent
Technologies, CA, USA). Spectra were recorded using a 1D-NOESY pulse sequence with a
mixing time of 1 ms and a recycle time of 3.5 s, for water suppression. Spectra were acquired at
300K, with a spectral width of 6000 Hz, a 90° pulse, and 128 scans. Before Fourier transforma-
tion, the free induction decays (FID) were zero-filled to 64k and an exponential weighting
function was applied with a line-broadening factor of 0.5 Hz. Spectra were manually phased
and baseline corrected using MestReNova software (Version 9.0, Mestrelab Research S.L.).
Chemical shifts were referred to the TSP single resonance at 0.00 ppm. The assignment of
major resonances was performed on the basis of data published in the literature [19] and using
the database implemented in Chenomx NMR suite 7.1 (Chenomx Inc., Edmonton, Alberta,
Canada). The 1H NMR spectra were reduced to consecutive integrated spectral regions (bins)
of equal width (0.04 ppm) corresponding to the region 0.5–9.5 ppm. The spectral region
between 4.50 and 6.50 ppm was excluded from the analysis to remove artifacts arising from
water signal suppression, the broad urea resonance and spectral noise. The binning procedure
was performed by MestReNova. To minimize the effects of variable concentration among dif-
ferent samples, for each spectrum the bin integrated areas were normalized to 100. The final
data matrix was imported into the SIMCA-P+ (Version 13.0, Umetrics, Umeå, Sweden) statis-
tical software package.
Statistical analysis
Multivariate statistical analysis of 1H NMR spectral data
Multivariate statistical analysis of 1H NMR spectral data were performed by the unsupervised
Principal components Analysis (PCA) and the supervised Partial Least Square Discriminant
Analysis (PLS-DA) and its Orthogonal variant (OPLS-DA), as implemented in SIMCA soft-
ware package. PCA is an explorative chemometric tool useful to check trends between samples
and variables, presence of outliers, and deviating features in the data. PLS-DA is a classification
tool based on PLS approach where the y-vector is the class label, in pairwise DA the dummy
variables, 0 and 1, are given to the two classes. OPLS-DA is a variant of PLS-DA, where separa-
tion between classes is forced in the first component (the “predictive” component) and further
Metabolomics and Chronic Pain
PLOS ONE | DOI:10.1371/journal.pone.0150476 March 2, 2016 3 / 10
components, orthogonal to the first, only express intra-class variability. The classification
power of models is expressed by the correlation coefficient R2Y. The DA models were vali-
dated by performing a series of tests such as cross-validation, in which samples are split into
groups (taking care that in each set, samples of both classes were present) and their member-
ship predicted, result of this procedure is the parameter Q2Y (the classification power in
cross-validation). A Q2Y value very different from R2Y is index of an overfitting in the origi-
nal model, a difference value larger than 0.3 has to be taken with caution. Results of the per-
mutation test with n = 400 were also checked [20]. The appropriate number of PCs for each
model was based on cross validation, in fact, although the variance explained by the model
(R2X and R2Y, for PCA and PLS-DA, respectively) will increase with subsequent compo-
nents, the classification power of the model in cross-validation (Q2) does not automatically
increase with incremental components, and thereafter, the inclusion of subsequent compo-
nents into the model will only add noise. Results of models can be shown as score plot where
samples are projected in the multivariate space, while influence of a variable in the classifica-
tion can be inferred by its magnitude (modelled covariation) and reliability (modelled
correlation) values for a predetermined class. High reliability means high effect and lower
uncertainty for the variable (putative biomarker), indeed, taking into account model correla-
tions, it is possible to investigate the reliability of small signals, that can contain precious
information, not highlighted by the model covariance under Pareto scaling [21].
Contingency table. PLS-DA is a hard modelling tool in which to each object/sample an
estimate of class membership to only one of the specified classes is given. Results of pairwise
OPLS-DA models have, therefore, binary outcome. As implemented in SIMCA software, a
value of prediction of belonging to one of the predefined classes is given for each sample. A
value close to one and above 0.65 indicate membership of the sample to the predefined class,
values between 0.35 and 0.65 that membership is borderline or uncertain, and values< 0.35
indicate that the sample does not belong to the class. These values were imported in a contin-
gency table, using the clinical evaluation as gold standard to define classes. Using values> 0.65
and considering as wrong attribution borderline values (between 0.35 and 0.65), which is the
most conservative way to discriminate membership, sensibility (true positive/affected), speci-
ficity (true negative/not affected), positive and negative predictive values (true positive/all posi-
tive, true negative/all negative, PPV and NPV, respectively) and accuracy (true positive and
negative/total population) of the models [22], were calculated. Analysis were performed with
InStat Prism 6.01, GraphPad1 Software, San Diego, California; USA. Statistical significance
was determined by two tailed Fischer Exact Test, and a p< 0.05 was deemed as significant.
Results
Urine samples were collected from patients diagnosed as suffering from nociceptive pain (NC,
n = 12) and neuropathic pain (NP, n = 25) and from controls (C, n = 37). Demographic and
clinical characteristics of pain patients and controls are reported in Table 1: women suffering
pain outnumbered men and the mean age was higher in patients with nociceptive pain.
1H NMR spectra were recorded for all samples. A representative 1H NMR spectrum of a
urine sample with major assignments is reported in S1 Fig. Spectral data were submitted to
MVA. An initial overview of samples distribution was obtained by PCA. In the score plot of
the first two (S2 Fig) components no grouping, no clusters, no trends of samples based on clini-
cal diagnosis, or confounding factors as gender and age were observed. To assess the classifica-
tion potential of the metabolomics approach, we carried out two-class DA and results of
classification models in terms of value of prediction of belonging to one of the two predefined
classes for each sample elaborated through the use of the contingency table. For each model,
Metabolomics and Chronic Pain
PLOS ONE | DOI:10.1371/journal.pone.0150476 March 2, 2016 4 / 10
control samples were chosen with age and gender matching to those of individuals suffering of
pain. At first, to ascertain whether subjects with pain syndromes have a different 1H NMR
urine metabolite profile with respect to the random control population, we performed a two
classes OPLS-DA, where both NP and NC samples were merged in an unique class: “pain”, and
compared to C class. Among the variables characterizing the pain profile, we found also man-
nitol, which is a common excipient of several drugs currently employed in the treatment of
pain syndromes. We therefore excluded the mannitol spectral region (from 3.62 to 3.90 ppm)
from the data matrix and we performed a new OPLS-DA analysis. The resulting “Pain vs. C”
model gave satisfactory results, in terms of good class separation and classification ability (the
corresponding R2Y and Q2Y values are reported in Table 2) and the resulting score plot, that
shows sample distribution in the multivariate space, is reported in Fig 1A.
Through the use of the contingency table, applied to the values of prediction of a sample to
belong to one of the two classes, sensitivity, specificity, accuracy and significance of the classifi-
cation were calculated and results, reported in Table 2, were quite satisfactory (detailed contin-
gency tables are reported in S2 Table). Based on these results, we can state that the 1H NMR
metabolite profile can well classify subjects with pain syndromes from that of control popula-
tion. Results of this model prompted us to find discriminant models able to classify the two
typologies of pain. Two-classes OPLS-DA of 1H NMR metabolite profiles of subjects diagnosed
as suffering of neuropathic pain were compared to the controls, matched for age and gender.
R2Y and Q2Y of the validated OPLS-DA “NP vs. C”model, and the calculated sensitivity,
Table 1. Demographic and clinical characteristics of subjects.
Sample size Pain duration (months)c PD scored Gender (M/W) Age (years)d
Pain group
NPa 25 25 (18–30) 22.31 ± 7.09 17/8 65 ± 15
NCb 12 19 (8–25) 2.90 ± 2.23 9/3 71 ± 14
Control group 37 26/11 55 ± 13
NP, neuropathic; NC, nociceptive; M/W, men/women.
aTrigeminal Neuralgia (n = 2), Thalamic Syndrome (n = 1), Phantom Limb (n = 2), Spinal Stenosis (n = 2), Postherpetic Neuralgia (n = 4), Fibromyalgia
(n = 1), Failed Low Back Surgery (n = 3), Diabetic Polyneuropathy (n = 1), CPRS I (n = 2), Postsurgical Pain (n = 4), Post Actinic Neuralgia (n = 1),
Radicular Pain (n = 3).
bLow Back Pain (n = 2), Sacroileitis (n = 1), Polyarthritis (n = 6), Psoriasic Arthritis (n = 1), Gonalgie (n = 1), Coxarthritis (n = 1).
cvalues expressed as the median (range).
dvalues are expressed as the mean ± standard deviation.
doi:10.1371/journal.pone.0150476.t001
Table 2. Results of samples classification for the different two-classes discriminant models.
Number of Samplesa OPLS-DA
parametersb
Contingency Table
Model NP NC C R2Y Q2Y Sensitivity Speciﬁcity Accuracy p value
Pain vs. C 25 12 37 0.80 0.66 0.86 0.95 0.90 <0.0001
NP vs. C 25 - 25 0.83 0.65 0.92 0.92 0.92 <0.0001
NC vs. C - 12 12 0.88 0.64 0.67 0.92 0.79 0.01
NP vs. NC 25 12 - 0.74 0.41 0.88 0.83 0.86 <0.0001
aNeuropathic pain (NP), nociceptive pain (NC), matched controls (C).
bClassiﬁcation power (R2Y), classiﬁcation power in cross-validation (Q2Y) of models.
doi:10.1371/journal.pone.0150476.t002
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specificity and accuracy are reported in Table 2. Analogously, pairwise OPLS-DA of 1H NMR
metabolite profiles of subjects diagnosed as suffering of nociceptive pain were compared to
the controls matched for age and gender. R2Y and Q2Y of the validated OPLS-DA “NC vs. C”
model and the calculated sensitivity, specificity and accuracy are reported in Table 2. The score
plots of these latter two models are shown in Fig 1B and 1C, respectively. At this point, we
wanted to take on the challenging task of discriminating subjects diagnosed as suffering of neu-
ropathic pain from those suffering of nociceptive pain. 1H NMR metabolite profile of NP and
NC samples were compared. The OPLS-DA gave good performance, R2Y and Q2Y of the vali-
dated OPLS-DA “NP vs. NC” model and the calculated sensitivity, specificity and accuracy are
reported in Table 2. The resulting score plot is shown in Fig 1D.
Although aimed at finding a good classification tool, we turned our attention also to the
metabolites that mostly contribute to class discrimination. To this goal, we analyzed the vari-
able loadings values along the predictive component of the OPLS-DA “NP vs. NC”model and
we found that urine of patients classified as affected by neuropathic pain are characterized by
higher levels of choline and phosphocholine, citrate, alanine and taurine, when compared with
those of patients with nociceptive pain.
Analyzing the overall results summarized in Table 2, it is clear that a good level of classifica-
tion can be obtained by pairwise OPLS-DA of 1H NMR spectral data of urine samples. R2Y
Fig 1. OPLS-DA score plots in the predictive (x-axis) and orthogonal (y-axis) components of 1H NMR spectral data of urine samples. A) “Pain vs. C”
model. B) “NP vs. C”model. C) “NC vs. C”model. D) “NP vs. NC”model. Separation of classes is maximized along the predictive component, while the
orthogonal component accounts for intra-class variability. Ellipse indicates the confidence region. Pain: neuropathic and nociceptive pain samples—inverted
grey triangles; C: matched control samples—green circles; NP: neuropathic pain samples—red squares; NC nociceptive pain samples—blue triangles.
Details of OPLS-DAmodels performance are given in S1 Table.
doi:10.1371/journal.pone.0150476.g001
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values were approximately 0.80 with lower value (0.74) in the “NP vs. NC” model, thus assess-
ing a high classification power of models. Q2Y values, that express the classification power in
cross-validation were between 0.66 and 0.41, obviously lower than the corresponding R2Y. The
“NP vs. NC” model had the lowest Q2Y value and a difference between R2Y and Q2Y> 0.3,
indicating a weak classification performance. Interpretation of these latter results is that NP
and NC can be well discriminated from controls, while when compared each other they pro-
duced less robust classifications. In general, contingency tables for all models showed high val-
ues of accuracy (between 0.79 and 0.92, Table 2 and S2 Table) all highly significant, with lower
value of accuracy for “NC vs. C”model. In this approach we have been extremely conservative,
deeming as false attributions even uncertain ones (e.g. in the “NP vsNC” model, the 2 false
negative NP were not classified as NC, but as borderline). It is worth noting that using 0.5 as a
threshold instead of 0.65 in the interpretation of OPLS-DA prediction values of belonging to a
class, in order to avoid uncertain attributions (as often performed in previous literature [23]),
would have led to even higher accuracy.
Discussion
Aim of this study was to investigate whether a 1H NMRmetabolomics approach can help in
formulate a definite pain diagnosis, as it is well known that obtaining unambiguous results
from clinical scores is a major issue for patients suffering from chronic pain. Very often, subjec-
tive perception of pain is influenced by other problems, such as psychological, adaptive, and
conflicting statuses. Moreover, differential diagnosis between neuropathic and nociceptive pain
can be very difficult, especially for non-specialists. This can lead to misdiagnosis and inappro-
priate treatment, exposing patients to prolonged suffering and unjustified risk of drugs adverse
reactions, and leading to increasing costs for the national health systems. Our discriminating
models are quite robust and the sensitivity and specificity of classification are satisfactorily
high. We were able to classify subjects suffering from pain from a control group, and to differ-
entiate neuropathic from nociceptive pain.
In general, contingency tables for all models showed high values of accuracy all highly sig-
nificant. Analyzing the overall results, we can stated that NP can be better discriminated from
controls than NC, indeed, lower value of accuracy was obtained when nociceptive pain and
control group were compared. Although its classification power was affected by a high error
(low Q2Y value), the model “NP vs. NC” showed a sensibility (accuracy = 0.86) higher than
common used scores in diagnosing neuropathic pain. In fact, the efforts to identify a unique
pattern of signs and symptoms for each kind of pain reached, at their best, a diagnostic cer-
tainty in about 80% of cases [1]. Indeed, not even the use of different questionnaires for the
identification of pain brings fulfilling results in clinical practice. It is worth to remind that we
choose to be extremely conservative, a less severe approach would have led to even higher
accuracy.
As for the discriminant metabolites, we want to focus on choline and phosphocholine, ala-
nine and taurine. The role of choline in the body is complex being involved in cell-membrane
signaling (phospholipids), lipid transport (lipoproteins), methyl group metabolism (homocys-
teine reduction), and synthesis of the neurotransmitter acetylcholine [24]. It is the commonest
polar head group of phospholipids and sphingomyelins, the major amphipathic constituents of
cells membranes, the latter especially in the myelin sheath that electrically insulates the nerve
cell axons. Increased levels of choline and phosphocholine are regarded as biomarkers of cellu-
lar membranes turnover in neoplasms, demyelination and gliosis [25]. As mentioned in the
introduction, several authors, investigating on the metabolic basis of chronic pain, found modi-
fications of the levels of those metabolites, among which phosphatidylcholine, involved in the
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sphingomyelin-ceramide metabolism [12, 17, 26]. The up-regulation of and phosphocholine
found in our NP group, when compared to NC, corroborates the previous finding of a damage
of nervous system linked to neuropathic pain. In fact, by its most recent definition, neuropathic
pain is always associated with a nervous system lesion [27]. Alanine has been indicated as brain
biomarker of apoptosis and cellular stress [28, 29]. Higher levels of alanine have been detected
also in meningioma, following ischemia [1, 30, 31], and in animals encephalopathies [32].
Release of the inhibitory aminoacid taurine has been observed in neural cell damage/stress
[33]. All these findings indicate that the neuropathic pain biomarkers here found, reflect neu-
ronal damage involvement.
The lower classification power related to NC pain, either versus controls or versus NP,
may be correlated to the fact that most (10 out of 12) of our NC patients suffer of osteoarticu-
lar (OA) pain. OA pain compared to NP pain, represents a still normal physiological
response to an inflammatory syndrome, while NP pain generates a more extreme pathophys-
iological condition that can massively affects the pain pathways. Moreover, we also have to
take into consideration the possible existence, in some patients with long lasting osteoarthri-
tis, of a neuropathic component and related metabolic features, as recently postulated by
Thakur et al. [34]. In this latter paper, it has been reported that the possible cause for this is
the pathological spread of new neural terminations in affected joints. Therefore, the possible
existence of such cases, can affect the results of our classification models, and further investi-
gations are needed.
Conclusions
In this exploratory study, for the first time, we investigated the ability of a 1H NMRmetabolo-
mics approach to differentiate between two types of chronic pain. In fact, we identified pain
suffering patients from controls, and we were also able to discriminate between patients
affected by neuropathic pain from those affected by nociceptive pain. The major limitation of
this study is the quite low sample size, especially for the nociceptive pain group, which prevents
us to generalize the obtained results. Moreover, it was hard to obtain a perfect age-matching
among the various groups of subjects, due to epidemiological characteristics of the studied pop-
ulations, as controls were mostly patients undergoing elective minor surgery.
As a suggestion for future development, we “throw the gauntlet” of creating a network for
the best possible definition of a 1H NMRmetabolite profile associated with different kinds of
pain. Thanks to the fast growing area of technologies, nowadays a good level NMR spectrome-
ter is relatively easy to find in Health facilities. The high reproducibility of NMR data among
different laboratories may allow the collection of a huge data bank. We are not even excluding
the possibility that such an approach could lead to the metabolic characterization of more than
the two profiles investigated in the present work. This could be extremely important for physi-
cians and, whenever translated into clinical practice, could allow a more accurate differential
pain diagnosis, even if performed by non-specialists. If so, patients would avoid misdiagnosis
and inappropriate treatment with a lowered burden of suffering and unjustified risk of drugs
adverse reactions. National Health Systems would benefit from cost reductions.
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